Brainstorm Cell Therapeutics INC Form 4 insider transactions
OQB
Chaim Lebovits, CEO of Brainstorm Cell Therapeutics, files an amendment to a previous SEC Form 4 to correct a transaction code error related to a common stock purchase.
OQB
Chaim Lebovits, CEO of Brainstorm Cell Therapeutics, files an amendment to a previous SEC Form 4 to correct transaction codes related to recent stock purchases.
OQB
Ibrahim B. Dagher, Chief Medical Officer of Brainstorm Cell Therapeutics, sold 63,000 shares of common stock at an average price of $0.3503.
OQB
EVP and COO Hartoun Hartounian of Brainstorm Cell Therapeutics acquires 30,000 shares of common stock and options to purchase 60,000 shares.
OQB
Chaim Lebovits, President and CEO of Brainstorm Cell Therapeutics, recently acquired 15,000 shares of common stock at an average price of $0.5183.
OQB
Chaim Lebovits, President and CEO of Brainstorm Cell Therapeutics, recently acquired 50,000 shares of common stock through direct purchases.
OQB
Chaim Lebovits, President and CEO of Brainstorm Cell Therapeutics, recently acquired additional shares of the company's common stock through a series of transactions.
OQB
Chaim Lebovits, President and CEO of Brainstorm Cell Therapeutics, recently acquired 66,300 shares of common stock at an average price of $0.3743.
OQB
Chaim Lebovits, CEO of Brainstorm Cell Therapeutics, recently acquired 135,000 shares of common stock at an average price of $0.3753 per share.
OQB
Chaim Lebovits, President and CEO of Brainstorm Cell Therapeutics, recently acquired 15,000 shares of common stock at a price of $0.5199 per share.
OQB
Chaim Lebovits, President and CEO of Brainstorm Cell Therapeutics, recently acquired additional shares of the company's common stock through multiple transactions.
OQB
Stacy Lindborg, Co-Chief Executive Officer of Brainstorm Cell Therapeutics, reports acquiring 241,935 shares of common stock through restricted stock awards.
OQB
Uri Yablonka, EVP & Chief Business Officer of Brainstorm Cell Therapeutics, acquired 109,426 shares of common stock through a restricted stock award on March 11, 2024.
OQB
Alla Patlis, Interim CFO & Controller of Brainstorm Cell Therapeutics, reports the acquisition of 65,246 shares of common stock through restricted stock awards.
OQB
Chaim Lebovits, CEO of Brainstorm Cell Therapeutics, received restricted stock awards and is deemed the beneficial owner of shares held by ACCBT Corp. and ACC International Holdings Ltd.